NEWS

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer. "Bringing new biosimilars to patients, especiall... read more
14 Sep 2017
  • FDA
Found in 2009, Finetech Industry Limited is specialized in research chemicals to pharmaceutical companies, universities, biotech companies, healthcare industries, contract research organizations and etc. We are serving the customers worldwide with over 5000 compounds in stock. New and un... read more
  • Finetech
Novartis, a global leader in Immunology & Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx® from a Phase III long-term extension study in patients with moderate-to-severe plaque psoriasis[1]. Data will be presented at a key medical congress in the second ... read more
14 Jul 2017
  • Novartis
AstraZeneca announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-developed with patients and caregivers using research led by AstraZeneca and patient community advocates to ensure a deep unde... read more
05 Apr 2017
  • AstraZeneca
Amgen (NASDAQ:AMGN) and CytomX Therapeutics, Inc., (NASDAQ:CTMX) today announced that the companies have entered into a strategic collaboration in immuno-oncology. The companies will co-develop a CytomX ProbodyTM T-cell engaging bispecific against the Epidermal Growth Factor Receptor (EGFR), a h... read more
03 Oct 2017
  • Amgen
With the founding of BI X as independent subsidiary Boehringer Ingelheim will focus on breakthrough innovative digital solutions in healthcare from idea to pilot. The start-up will work closely together with all three business units of the company - Human Pharma, Animal Health and Biopharmaceuti... read more
12 Jun 2017
  • Boehringer Ingelheim
Finetech's New website is online now.Thanks a lot for your support in the past years, we will continuing to supply high quality products and service for you.Now we have add many new date about products details to our product information,and we are keeping update about the listing.We hope we can b... read more
04 Jan 2018
  • Finetech
We introduce Finetech Industry limited as a supplier of customer synthesis. Today, we would like to introduce one of our new product with kg scale supply. Please contact with sales@finetechnology-ind.com to inquiry about the product. Appearance: White to light green powder Assay:98% Fo... read more
10 Sep 2018
  • 53332-27-7
Roche (SIX: RO, ROG; OTCQX:RHHBY), has announced the launch of the NAVIFY Tumor Board solution, a clinical workflow and decision support software that optimises decision-making for cancer patient case reviews in tumor boards, or multi-disciplinary team meetings. The solution fundamentally chan... read more
09 Oct 2017
  • Roche
Sanofi and Regeneron Pharmaceuticals, Inc. have announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or m... read more
27 May 2017
  • Sanofi
The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body wher... read more
23 May 2017
  • FDA
Pfizer Inc. (NYSE:PFE) announced that the United States (U.S.) Food and Drug Administration (FDA) has approved IXIFI™ (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade® (infliximab) for all eligible indica... read more
15 Sep 2017
  • FDA
Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entresto® (sacubitril/valsartan) tablets improved glycemic control, as assessed by hemoglobin A1c (HbA1c) testing, compared to A... read more
20 Apr 2017
  • Novartis